The DOI matches its Crossref record; 51 of the 51 references it cites were found in a registry or an index.
Effect of HIV Antibody VRC01 on Viral Rebound after Treatment Interruption
Open accessAbstract
BACKGROUND: The discovery of potent and broadly neutralizing antibodies (bNAbs) against human immunodeficiency virus (HIV) has made passive immunization a potential strategy for the prevention and treatment of HIV infection. We sought to determine whether passive administration of VRC01, a bNAb targeting the HIV CD4-binding site, can safely prevent or delay plasma viral rebound after the discontinuation of antiretroviral therapy (ART). METHODS: We conducted two open-label trials (AIDS Clinical Trials Group [ACTG] A5340 and National Institutes of Health [NIH] 15-I-0140) of the safety, side-effect profile, pharmacokinetic properties, and antiviral activity of VRC01 in persons with HIV infection who were undergoing interruption of ART. RESULTS: A total of 24 participants were enrolled, and one serious alcohol-related adverse event occurred. Viral rebound occurred despite plasma VRC01 concentrations greater than 50 μg per milliliter. The median time to rebound was 4 weeks in the A5340 trial and 5.6 weeks in the NIH trial. Study participants were more likely than historical controls to have viral suppression at week 4 (38% vs. 13%, P=0.04 by a two-sided Fisher's exact test in the A5340 trial; and 80% vs. 13%, P<0.001 by a two-sided Fisher's exact test in the NIH trial) but the difference was not significant at week 8. Analyses of virus populations before ART as well as before and after ART interruption showed that VRC01 exerted pressure on rebounding virus, resulting in restriction of recrudescent viruses and selection for preexisting and emerging antibody neutralization-resistant virus. CONCLUSIONS: VRC01 slightly delayed plasma viral rebound in the trial participants, as compared with historical controls, but it did not maintain viral suppression by week 8. In the small number of participants enrolled in these trials, no safety concerns were identified with passive immunization with a single bNAb (VRC01). (Funded by the National Institute of Allergy and Infectious Diseases and others; ACTG A5340 and NIH 15-I-0140 ClinicalTrials.gov numbers, NCT02463227 and NCT02471326 .).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Guindon, S., Dufayard, J.-F., Lefort, V., Anisimova, M., Hordijk, W., & Gascuel, O. (2010) · Systematic Biology · doi:10.1093/sysbio/syq010 · Cited by 18,376
The Efficacy of Azidothymidine (AZT) in the Treatment of Patients with AIDS and AIDS-Related Complex
Fischl, M. A., Richman, D. D., Grieco, M. H., Gottlieb, M. S., Volberding, P. A., Laskin, O. L., Leedom, J. M., Groopman, J. E., Mildvan, D., Schooley, R. T., et al. (1987) · New England Journal of Medicine · doi:10.1056/nejm198707233170401 · Cited by 2,995
HyPhy: hypothesis testing using phylogenies
Pond, S. L. K., Frost, S. D. W., & Muse, S. V. (2005) · Bioinformatics · doi:10.1093/bioinformatics/bti079 · Cited by 2,866
Hammer, S. M., Squires, K. E., Hughes, M. D., Grimes, J. M., Demeter, L. M., Currier, J. S., Eron, J. J., Feinberg, J. E., Balfour, H. H., Deyton, L. R., et al. (1997) · New England Journal of Medicine · doi:10.1056/nejm199709113371101 · Cited by 2,640
CD4+ Count–Guided Interruption of Antiretroviral Treatment
(2006) · New England Journal of Medicine · doi:10.1056/nejmoa062360 · Cited by 2,231
Recovery of replication-competent HIV despite prolonged suppression of plasma viremia
Wong, J. K., Hezareh, M., Günthard, H. F., Havlir, D. V., Ignacio, C. C., Spina, C. A., & Richman, D. D. (1997) · Science · doi:10.1126/science.278.5341.1291 · Cited by 2,186
Finzi, D., Blankson, J., Siliciano, J. D., Margolick, J. B., Chadwick, K., Pierson, T., Smith, K., Lisziewicz, J., Lori, F., Flexner, C., et al. (1999) · Nature Medicine · doi:10.1038/8394 · Cited by 2,119
Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy
Chun, T.-W., Stuyver, L., Mizell, S. B., Ehler, L. A., Mican, J. A. M., Baseler, M., Lloyd, A. L., Nowak, M. A., & Fauci, A. S. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.24.13193 · Cited by 1,977
Self-citationKeele, B. F., Giorgi, E. E., Salazar-Gonzalez, J. F., Decker, J. M., Pham, K. T., Salazar, M. G., Sun, C., Grayson, T., Wang, S., Li, H., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0802203105 · Cited by 1,912
Gulick, R. M., Mellors, J. W., Havlir, D., Eron, J. J., Gonzalez, C., McMahon, D., Richman, D. D., Valentine, F. T., Jonas, L., Meibohm, A., et al. (1997) · New England Journal of Medicine · doi:10.1056/nejm199709113371102 · Cited by 1,885
Rational Design of Envelope Identifies Broadly Neutralizing Human Monoclonal Antibodies to HIV-1
Wu, X., Yang, Z.-Y., Li, Y., Hogerkorp, C.-M., Schief, W. R., Seaman, M. S., Zhou, T., Schmidt, S. D., Wu, L., Xu, L., et al. (2010) · Science · doi:10.1126/science.1187659 · Cited by 1,730
Self-citationHIV with Reduced Sensitivity to Zidovudine (AZT) Isolated During Prolonged Therapy
Larder, B. A., Darby, G., & Richman, D. D. (1989) · Science · doi:10.1126/science.2467383 · Cited by 1,559
Mascola, J. R., Stiegler, G., VanCott, T. C., Katinger, H., Carpenter, C. B., Hanson, C. E., Beary, H., Hayes, D., Frankel, S. S., Birx, D. L., et al. (2000) · Nature Medicine · doi:10.1038/72318 · Cited by 1,250
Self-citationStructural Basis for Broad and Potent Neutralization of HIV-1 by Antibody VRC01
Zhou, T., Georgiev, I., Wu, X., Yang, Z.-Y., Dai, K., Finzi, A., Do Kwon, Y., Scheid, J. F., Shi, W., Xu, L., et al. (2010) · Science · doi:10.1126/science.1192819 · Cited by 1,130
Self-citationDavey, R. T., Bhat, N., Yoder, C., Chun, T.-W., Metcalf, J. A., Dewar, R., Natarajan, V., Lempicki, R. A., Adelsberger, J. W., Miller, K. D., et al. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.26.15109 · Cited by 849
Self-citationViraemia suppressed in HIV-1-infected humans by broadly neutralizing antibody 3BNC117
Caskey, M., Klein, F., Lorenzi, J. C. C., Seaman, M. S., West, A. P., Buckley, N., Kremer, G., Nogueira, L., Braunschweig, M., Scheid, J. F., et al. (2015) · Nature · doi:10.1038/nature14411 · Cited by 767
A cladistic measure of gene flow inferred from the phylogenies of alleles.
Slatkin, M., & Maddison, W. P. (1989) · Genetics · doi:10.1093/genetics/123.3.603 · Cited by 731
Barouch, D. H., Whitney, J. B., Moldt, B., Klein, F., Oliveira, T. Y., Liu, J., Stephenson, K. E., Chang, H.-W., Shekhar, K., Gupta, S., et al. (2013) · Nature · doi:10.1038/nature12744 · Cited by 644
A New Statistic for Detecting Genetic Differentiation
Hudson, R. R. (2000) · Genetics · doi:10.1093/genetics/155.4.2011 · Cited by 637
Unifying the derivations for the Akaike and corrected Akaike information criteria
Cavanaugh, J. E. (1997) · Statistics & Probability Letters · doi:10.1016/s0167-7152(96)00128-9 · Cited by 626
Salazar-Gonzalez, J. F., Bailes, E., Pham, K. T., Salazar, M. G., Guffey, M. B., Keele, B. F., Derdeyn, C. A., Farmer, P., Hunter, E., Allen, S., et al. (2008) · Journal of Virology · doi:10.1128/jvi.02660-07 · Cited by 596
Therapeutic antibodies for human diseases at the dawn of the twenty-first century
Brekke, O. H., & Sandlie, I. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd984 · Cited by 550
Antibody-based protection against HIV infection by vectored immunoprophylaxis
Balazs, A. B., Chen, J., Hong, C. M., Rao, D. S., Yang, L., & Baltimore, D. (2012) · Nature · doi:10.1038/nature10660 · Cited by 545
HIV therapy by a combination of broadly neutralizing antibodies in humanized mice
Klein, F., Halper-Stromberg, A., Horwitz, J. A., Gruell, H., Scheid, J. F., Bournazos, S., Mouquet, H., Spatz, L. A., Diskin, R., Abadir, A., et al. (2012) · Nature · doi:10.1038/nature11604 · Cited by 500
Lynch, R. M., Boritz, E., Coates, E. E., DeZure, A., Madden, P., Costner, P., Enama, M. E., Plummer, S., Holman, L., Hendel, C. S., et al. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aad5752 · Cited by 465
Self-citationAntibody-mediated immunotherapy of macaques chronically infected with SHIV suppresses viraemia
Shingai, M., Nishimura, Y., Klein, F., Mouquet, H., Donau, O. K., Plishka, R., Buckler-White, A., Seaman, M., Piatak, M., Lifson, J. D., et al. (2013) · Nature · doi:10.1038/nature12746 · Cited by 455
Re-emergence of HIV after stopping therapy
Chun, T.-W., Davey, R. T., Engel, D., Lane, H. C., & Fauci, A. S. (1999) · Nature · doi:10.1038/44755 · Cited by 428
Self-citationPhenotypic properties of transmitted founder HIV-1
Parrish, N. F., Gao, F., Li, H., Giorgi, E. E., Barbian, H. J., Parrish, E. H., Zajic, L., Iyer, S. S., Decker, J. M., Kumar, A., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1304288110 · Cited by 422
Antibody responses to envelope glycoproteins in HIV-1 infection
Burton, D. R., & Mascola, J. R. (2015) · Nature Immunology · doi:10.1038/ni.3158 · Cited by 385
Self-citationEnhanced neonatal Fc receptor function improves protection against primate SHIV infection
Ko, S.-Y., Pegu, A., Rudicell, R. S., Yang, Z.-Y., Joyce, M. G., Chen, X., Wang, K., Bao, S., Kraemer, T. D., Rath, T., et al. (2014) · Nature · doi:10.1038/nature13612 · Cited by 384
Self-citationBinley, J. M., Lybarger, E. A., Crooks, E. T., Seaman, M. S., Gray, E., Davis, K. L., Decker, J. M., Wycuff, D., Harris, L., Hawkins, N., et al. (2008) · Journal of Virology · doi:10.1128/jvi.01762-08 · Cited by 355
Self-citationHIV-1 therapy with monoclonal antibody 3BNC117 elicits host immune responses against HIV-1
Schoofs, T., Klein, F., Braunschweig, M., Kreider, E. F., Feldmann, A., Nogueira, L., Oliveira, T., Lorenzi, J. C. C., Parrish, E. H., Learn, G. H., et al. (2016) · Science · doi:10.1126/science.aaf0972 · Cited by 313
Self-citationJohnson, P. R., Schnepp, B. C., Zhang, J., Connell, M. J., Greene, S. M., Yuste, E., Desrosiers, R. C., & Reed Clark, K. (2009) · Nature Medicine · doi:10.1038/nm.1967 · Cited by 310
A single injection of anti-HIV-1 antibodies protects against repeated SHIV challenges
Gautam, R., Nishimura, Y., Pegu, A., Nason, M. C., Klein, F., Gazumyan, A., Golijanin, J., Buckler-White, A., Sadjadpour, R., Wang, K., et al. (2016) · Nature · doi:10.1038/nature17677 · Cited by 306
Self-citationLi, J. Z., Etemad, B., Ahmed, H., Aga, E., Bosch, R. J., Mellors, J. W., Kuritzkes, D. R., Lederman, M. M., Para, M., & Gandhi, R. T. (2015) · AIDS · doi:10.1097/qad.0000000000000953 · Cited by 287
The growth and potential of human antiviral monoclonal antibody therapeutics
Marasco, W. A., & Sui, J. (2007) · Nature Biotechnology · doi:10.1038/nbt1363 · Cited by 284
Rothenberger, M. K., Keele, B. F., Wietgrefe, S. W., Fletcher, C. V., Beilman, G. J., Chipman, J. G., Khoruts, A., Estes, J. D., Anderson, J., Callisto, S. P., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1414926112 · Cited by 277
VRC 602 Study Team, Ledgerwood, J. E., Coates, E. E., Yamshchikov, G., Saunders, J. G., Holman, L., Enama, M. E., DeZure, A., Lynch, R. M., Gordon, I., et al. (2015) · Clinical and Experimental Immunology · doi:10.1111/cei.12692 · Cited by 247
Self-citationPegu, A., Yang, Z.-Y., Boyington, J. C., Wu, L., Ko, S.-Y., Schmidt, S. D., McKee, K., Kong, W.-P., Shi, W., Chen, X., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3008992 · Cited by 242
Self-citationHIV reservoirs as obstacles and opportunities for an HIV cure
Chun, T.-W., Moir, S., & Fauci, A. S. (2015) · Nature Immunology · doi:10.1038/ni.3152 · Cited by 232
Self-citationEarly Low-Titer Neutralizing Antibodies Impede HIV-1 Replication and Select for Virus Escape
Bar, K. J., Tsao, C.-Y., Iyer, S. S., Decker, J. M., Yang, Y., Bonsignori, M., Chen, X., Hwang, K.-K., Montefiori, D. C., Liao, H.-X., et al. (2012) · PLoS Pathogens · doi:10.1371/journal.ppat.1002721 · Cited by 180
Self-citationModeling sequence evolution in acute HIV-1 infection
Lee, H. Y., Giorgi, E. E., Keele, B. F., Gaschen, B., Athreya, G. S., Salazar-Gonzalez, J. F., Pham, K. T., Goepfert, P. A., Michael Kilby, J., Saag, M. S., et al. (2009) · Journal of Theoretical Biology · doi:10.1016/j.jtbi.2009.07.038 · Cited by 173
Kearney, M. F., Wiegand, A. P., Shao, W., Coffin, J. M., Mellors, J. W., Lederman, M. M., Gandhi, R. T., Keele, B. F., & Li, J. Z. (2015) · Journal of Virology · doi:10.1128/jvi.02139-15 · Cited by 154
Kong, R., Louder, M. K., Wagh, K., Bailer, R. T., deCamp, A. C., Greene, K., Gao, H., Taft, J. D., Gazumyan, A., Liu, C., et al. (2014) · Journal of Virology · doi:10.1128/jvi.03136-14 · Cited by 140
Self-citationThe Development of CD4 Binding Site Antibodies during HIV-1 Infection
Lynch, R. M., Tran, L. M., Louder, M. K., Schmidt, S. D., Cohen, M. S., DerSimonian, R., Euler, Z., Gray, E. S., Karim, S. S. A., Kirchherr, J., et al. (2012) · Journal of Virology · doi:10.1128/jvi.00734-12 · Cited by 139
Self-citationRecco: recombination analysis using cost optimization
Maydt, J., & Lengauer, T. (2006) · Bioinformatics · doi:10.1093/bioinformatics/btl057 · Cited by 118
Towards HIV-1 remission: potential roles for broadly neutralizing antibodies
Halper-Stromberg, A., & Nussenzweig, M. C. (2016) · Journal of Clinical Investigation · doi:10.1172/jci80561 · Cited by 78
Broadly neutralizing antibodies suppress HIV in the persistent viral reservoir
Chun, T., Murray, D., Justement, J. S., Blažková, J., Hallahan, C. W., Fankuchen, O., Gittens, K. R., Benko, E., Kovacs, C. M., Moir, S. L., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1414148111 · Cited by 72
Self-citationBouvin-Pley, M., Morgand, M., Meyer, L., Goujard, C., Moreau, A., Mouquet, H., Nussenzweig, M. C., Pace, C. S., Ho, D. D., Björkman, P. J., et al. (2014) · Journal of Virology · doi:10.1128/jvi.02083-14 · Cited by 57
Postexposure immunoprophylaxis of primary isolates by an antibody to HIV receptor complex
Wang, C. Y., Sawyer, L. S. W., Murthy, K. K., Fang, X., Walfield, A. M., John Ye, A., Wang, J. J. G., Chen, P. D., Li, M. L., Salas, M. T., et al. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.18.10367 · Cited by 38
Self-citationBednar, M. M., Hauser, B. M., Zhou, S., Jacobson, J. M., Eron, J. J., Frank, I., & Swanstrom, R. I. (2016) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiw172 · Cited by 27
Cited by
The role of IgG Fc receptors in antibody-dependent enhancement
Bournazos, S., Gupta, A., & Ravetch, J. V. (2020) · Nature Reviews Immunology · doi:10.1038/s41577-020-00410-0 · Cited by 617
Two Randomized Trials of Neutralizing Antibodies to Prevent HIV-1 Acquisition
Corey, L., Gilbert, P. B., Juraska, M., Montefiori, D. C., Morris, L., Karuna, S. T., Edupuganti, S., Mgodi, N. M., deCamp, A. C., Rudnicki, E., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2031738 · Cited by 538
Self-citationCombination therapy with anti-HIV-1 antibodies maintains viral suppression
Mendoza, P., Gruell, H., Nogueira, L., Pai, J. A., Butler, A. L., Millard, K., Lehmann, C., Suárez, I., Oliveira, T. Y., Lorenzi, J. C. C., et al. (2018) · Nature · doi:10.1038/s41586-018-0531-2 · Cited by 521
Antibody 10-1074 suppresses viremia in HIV-1-infected individuals
Caskey, M., Schoofs, T., Gruell, H., Settler, A., Karagounis, T., Kreider, E. F., Murrell, B., Pfeifer, N., Nogueira, L., Oliveira, T. Y., et al. (2017) · Nature Medicine · doi:10.1038/nm.4268 · Cited by 487
Self-citationRecent progress in broadly neutralizing antibodies to HIV
Sok, D., & Burton, D. R. (2018) · Nature Immunology · doi:10.1038/s41590-018-0235-7 · Cited by 407
Metadata
- Authors
- Bar, K. J., Sneller, M. C., Harrison, L. J., Justement, J. S., Overton, E. T., Petrone, M. E., Salantes, D. B., Seamon, C. A., Scheinfeld, B., Kwan, R. W., Learn, G. H., Proschan, M. A., Kreider, E. F., Blazkova, J., Bardsley, M., Refsland, E. W., Messer, M., Clarridge, K. E., Tustin, N. B., Madden, P. J., Oden, K., O’Dell, S. J., Jarocki, B., Shiakolas, A. R., Tressler, R. L., Doria-Rose, N. A., Bailer, R. T., Ledgerwood, J. E., Capparelli, E. V., Lynch, R. M., Graham, B. S., Moir, S., Koup, R. A., Mascola, J. R., Hoxie, J. A., Fauci, A. S., Tebas, P., & Chun, T.-W.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2016-11-24
- Volume
- 375
- Issue
- 21
- Pages
- 2037-2050
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2557191642
- Cited by
- 455
- References
- 51
- FWCI
- 36.82
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.